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Background: Whether novel biomarkers improve risk prediction of mortality beyond standard cardiovascular disease
(CVD) risk markers in peripheral arterial disease (PAD) patients, and whether any such prediction differs with length of
follow-up, remains controversial. Our objective was to determine in patients with PAD whether novel biomarkers
improve prediction of CVD mortality and total mortality.
Methods: A cohort of 397 patients who were referred to a vascular lab had PAD diagnosed by noninvasive testing.
Fifty-eight percent also had coronary or cerebrovascular disease at baseline. Predictors of total, CVD, and non-CVD
mortality were assessed with Cox proportional hazards models, and the incremental value of predictors was evaluated
with both the C-statistic and the integrated discrimination improvement (IDI) index.
Results: Total mortality was 11% at 2-year follow-up and 65% at an average of 6.6-year of follow-up (maximum, 11.4
years). At 2 years, hs-CRP was a strong and significant predictor of mortality, with a hazard ratio (HR) of 1.56 per
standard deviation (P  .006). However, at full follow up, standard CVD risk markers were significant (age, gender,
ankle-brachial index, other CVD, and hypertension), but hs-CRP no longer showed a significant relationship (HR 1.12;
P  .11). None of the other biomarkers studied showed a significant independent association with mortality. Hs-CRP
improved the C-statistic and the IDI beyond standard risk markers at 2 years, but not at full follow-up.
Conclusions: hs-CRP was a strong predictor of short-term mortality in this cohort of PAD patients, while standard risk
markers were better at predicting longer-term mortality. ( J Vasc Surg 2010;52:85-90.)In recent years, several novel cardiovascular risk factors
including inflammatory, thrombotic, and fibrinolytic mark-
ers have been studied prospectively in populations of pri-
marily healthy participants at baseline. Reports of associa-
tions with cardiovascular disease (CVD) morbidity and
mortality have varied, although associations for highly sen-
sitive C-reactive protein (hs-CRP) have been fairly consis-
tent.1-3 Although some studies report relatively constant
predictive value for mortality throughout follow-up,4,5 sev-
eral reports have indicated that inflammatory markers were
better predictors of proximate early deaths than later
deaths.6-11 These reports were prospective studies in pop-
ulation-based cohorts, with the exception of one report
from a group of peripheral arterial disease (PAD) pa-
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doi:10.1016/j.jvs.2010.02.004tients.11 However, none of these studies employed receiver
operating characteristic (ROC) curves, C-statistics, or mea-
sures of misclassification to evaluate any changes in risk
prediction as a function of time.
Patients with vascular disease have a high risk of mor-
tality, primarily from CVD.12 To date, little evidence exists
on these newer risk markers from cohorts selected for
prevalent vascular disease at baseline. In an older cohort of
PAD patients, we evaluated the association of six biomark-
ers including inflammatory, thrombotic, fibrinolytic, and
atherosclerotic risk markers with short-term (at 2 years) and
longer-term (up to 11.4 years; average, 6.6 years) mortal-
ity. Total, CVD, and non-CVD mortality were separately
evaluated. Using the C-statistic and the integrated discrim-
ination improvement (IDI) index, we also determined the
degree to which biomarkers provided incremental informa-
tion in risk prediction and whether this differed between
near- and longer-term follow-up.
METHODS
Subjects were recruited between 1990 and 1994 from
patients who had been seen in the previous 10 years for
noninvasive lower extremity arterial testing at the vascular
laboratories of the San Diego Veterans Administration
Medical Center (SDVAMC) and the University of Califor-
nia San Diego Medical Center (UCSDMC). Out of 2265
patients having such visits, 481 were deceased and another
1272 could not be located or declined to participate.
Informed consent was obtained from the remaining 512
patients, who were included in the baseline visit for this
study. A prior analysis of this cohort found that participants
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pants and included a higher percentage of women (13% vs
8%), but were similar with respect to age.13 Among these
512 patients, PAD was confirmed by noninvasive testing in
397 patients who had a frozen blood sample at baseline and
mortality follow-up.
At baseline, subjects completed a health history ques-
tionnaire. Weight and height were measured. Standard
cardiovascular risk factors were measured at baseline. Be-
cause of extensive treatment in this high-risk population,
composite variables were created for hypertension (systolic
blood pressure [BP] 140 mm Hg, diastolic BP 90 mm
Hg, or medication use), dyslipidemia (total cholesterol to
HDL cholesterol ratio5 or medication use), and diabetes
(fasting glucose 125 mg/dL or diabetes history). Pack-
years of cigarette smoking were determined by multiplying
the number of years smoked by the average number of
packs smoked per day.
Eight biomarkers were measured from baseline serum
frozen and stored at -70° C. We have previously reported
the results for two biomarkers, N-terminal pro-brain-type
natriuretic peptide and lipoprotein-associated phospho-
lipase A2, neither of which showed a significant association
with mortality in this cohort.14,15 The remaining six bi-
omarkers can be grouped into three categories: 1) inflam-
matory markers: hs-CRP, serum amyloid A (SAA); 2)
thrombotic and fibrinolytic markers: D-dimer and platelet-
activating factor (PAF); and 3) atherogenicmarkers: homo-
cysteine and lipoprotein (a). Hs-CRP assay was performed
by an ultrasensitive immunotechnique on the Behring
BNII analyzer (Dade Behring, Newark, DE). The SAA and
Lp(a) assay was performed by an immunotechnique on the
Behring BNII analyzer (Dade Behring). D-dimer was
quantified using the Kamiya’s K-Assay D-dimer Kit (cata-
logue # KAI-900; Kamiya, Seattle, Wash). PAF was quan-
tified using Azwell’s Auto-PAF kit (code 274664847;
Azwell, Osaka, Japan). For both D-dimer and PAF, calibra-
tors and controls were run singly at the beginning and end
of each day. All samples were run in single point. Total
homocysteine was measured by HPLC with fluorometric
detection using reagents from BioRad Laboratories (Her-
cules, Calif).
At the baseline visit, systolic BP was measured in the
supine position at both ankles with a standard BP cuff, with
detection at the toe by photoplethysmography. Brachial
pressure was measured in both arms with the appropriate
size cuff, with photoplethysmographic detection at the
third finger. The ankle-brachial index (ABI) for each leg
was computed as the ratio of the ankle pressure for that leg
to the higher of the left and right brachial pressures. Be-
cause of the strong correlation between PAD and subcla-
vian stenosis, use of the higher brachial pressure was partic-
ularly important in this high-risk population.16 The peak
posterior tibial flow velocity was measured at each ankle.
PAD was defined as an ABI at either ankle of 1.00, or
1.40, or a peak posterior tibial flow velocity of 11
cm/sec, or previous leg revascularization (angioplasty or
surgery).12 CVD other than PAD was defined as a historyof angina, myocardial infarction, or coronary revasculariza-
tion, or a history of transient ischemic attack (TIA), stroke,
or carotid revascularization. This composite variable was
labeled “other CVD.”
Mortality in the study cohort was identified using So-
cial Security Administration data available through the end
of 2002. A certified nosologist coded the causes of death
based on death certificates obtained from state vital statis-
tics offices. Three endpoints were considered in the analy-
sis: all-causemortality, CVDmortality, and non-CVDmor-
tality. Mortality was classified based on the underlying
cause of death on the death certificate. CVD mortality was
identified by International Classification of Diseases, Ver-
sion 9 (ICD-9) codes 250 (diabetes mellitus), 395-396,
and 401-444. Deaths where the underlying cause was
diabetes mellitus were classified as CVD since the ICD
coding system allows a patient with an MI and stroke listed
on the death certificate to have diabetes mellitus as the
underlying cause of death. All other deaths were classified
as non-CVD mortality.
Subjects were tabulated by mortality status: alive, all-
cause mortality, and the mortality subsets of CVD and
non-CVD. Age- and gender-adjusted mean baseline values
of standard risk factors and the biomarkers were calculated
for each of these groups at longer-term (up to 11.4 years;
mean, 6.6 years) follow-up. For 2 years of follow-up, all
subjects except those censored had that precise follow-up
time. The final (and thus “full”) follow-up included a
maximum of 11.4 years and an average of 6.6 years. Among
the biomarkers, only homocysteine and PAF approximated
a normal distribution, so the natural log (ln) of each of the
remaining four biomarkers was utilized. For presentation of
a meaningful number, the geometric mean was back-calcu-
lated from the ln mean.
In this PAD cohort, the goal was to evaluate the
influences of the biomarkers while adjusting for other CVD
present at baseline, as well as the traditional CVD risk
factors, both for near- and longer-term follow up. Cox
proportional hazards models were fit for three endpoints
(all-cause mortality, CVD mortality, non-CVD mortality)
for 2 years and full follow-up, respectively. Thus, six sepa-
rate models were run. All the traditional risk factors were
included in thesemodels. To explore for nonlinear relation-
ships, each of the selected biomarkers was initially modeled
as quartiles, followed by modeling as a continuous variable.
To be retained in the final multivariate models, a biomarker
had to show an adjusted P value of.10 for both of the two
follow-up periods. Shoenfeld residuals confirmed that the
proportional hazards assumptions were met.17,18 Propor-
tional hazards models were also used to generate C statis-
tics, and the contribution of individual factors to the C
statistic at short- and longer-term follow-up was evaluated.
The IDI, a measure of the extent of correct reclassification
of cases and noncases by a risk variable, was calculated as
previously described.19 No adjustment was made for mul-
tiple comparisons, and P values are given. All analyses were
performed using SAS software.20 The study protocol was
approved by the institutional review boards of SDVAMC
myloid
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consent to participate in the study.
RESULTS
Full follow-up ranged from 10 days to 11.4 years
(average, 6.6 years). At 2 years, there were 45 deaths
(11.3%), 26 from CVD. By an average of 6.6-year follow-
up, 259 (65.2%) had died, 150 from CVD.
Table I shows mean levels or percentages of each of the
risk variables across the four vital status categories at full
follow-up. P values are for comparisons of survivors sepa-
rately to each of the three mortality groups. Older age and
male gender were strongly associated with total, CVD, and
non-CVDmortality. Thus, all other risk variables in Table I
were age- and gender-adjusted. Other CVD was signifi-
cantly associated with total and CVD mortality. Among
risk factors, hypertension and diabetes were the strongest
predictors for total and CVD mortality. The next stron-
gest correlate was hs-CRP, which showed borderline
Table I. Levels of standard risk markers and biomarkers at b
years)
Risk markers
Alive
N 138
Age 66.1
Female % 18.1
Age- and gender-adjusted standard
risk markers
Hypertension, % 70.6
CVD, % 48.4
Diabetes, % 28.0
Pack-years cigarettes 46.8
Dyslipidemia, % 48.5
Biomarkers
hs-CRP (mg/L) 2.83
SAA (mg/L) 0.49
D-dimer (ug/mL) 0.92
Homocysteine (mg/L) 14.64
PAF (IU/L) 645.83 6
Lp(a) (mg/dL) 11.41
CVD, Cardiovascular disease; PAF, platelet-activating factor; SAA, serum a
Table II. Hazard ratios for 2-year and full follow-up (mea
Risk markers
Total mortality
2 yr 6.6 yr
Age (10 yrs) 1.38 1.55
Female 0.50 0.62
Diabetes 2.11 1.30
ABI 0.24 0.41
Other CVD 0.92 1.35
Hypertension 1.12 1.52
Cigarette pack-yrs (40) 1.00 1.11
Dyslipidemia 1.13 1.10
Ln hs-CRP (SD) 1.56 1.12
ABI, Ankle-brachial index; CVD, cardiovascular disease.
Bold type denotes P  .05.associations with both CVD and non-CVD mortality(P .06). Pack-years of cigarettes was the next strongest
correlate and showed a stronger association with non-
CVD mortality, likely reflecting the significant numbers
of respiratory cancer and chronic obstructive pulmonary
disease (COPD) deaths in the latter category. The only
other variable which showed an association with a P
value .10 for any mortality category was dyslipidemia
for CVD mortality.
Table II shows the multivariable survival model results
for total, CVD, and non-CVD mortality at 2 years and full
follow-up. Because of missing data for one or more vari-
ables, 21 of the 397 PAD patients were excluded from the
multivariate models. Among the biomarkers, only hs-CRP
met the P .10 criterion inclusion for themodels. For total
mortality, at 2 years of follow-up, hs-CRPwas the strongest
predictor (hazard ratio [HR]  1.56 per SD; P  .006).
The only other significant predictor was diabetes (HR 
2.11; P  .018). At 6.6-year average follow-up, age, gen-
der, other CVD, and hypertension all showed positive and
e in survivors and decedents at full follow-up (mean, 6.6
Dead CVDmortality Non-CVDmortality
 259 N 150 N 109
1 (.001) 69.9 (.001) 70.5 (.001)
1 (.01) 6.0 (.01) 11.0 (.08)
0 (.01) 87.3 (.01) 79.5 (.09)
4 (.01) 69.6 (.01) 54.9 (.31)
4 (.01) 49.5 (.01) 35.0 (.26)
0 (.08) 53.6 (.19) 56.9 (.07)
7 (.34) 61.9 (.02) 42.3 (.33)
7 (.06) 3.45 (.15) 3.74 (.06)
8 (.12) 0.58 (.19) 0.59 (.17)
7 (.18) 1.02 (.40) 1.14 (.11)
4 (.34) 13.63 (.43) 13.43 (.38)
7 (.62) 664.00 (.44) 646.55 (.98)
2 (.25) 10.24 (.48) 9.05 (.16)
A.
.6 years) for total, CVD, and non-CVD mortality
CVD mortality Non-CVD mortality
2 yr 6.6 yr 2 yr 6.6 yr
1.21 1.64 1.59 1.46
0.00 0.45 1.65 0.84
2.14 1.53 1.90 1.00
0.04 0.14 2.73 1.39
0.92 1.69 1.07 1.06
3.99 1.92 0.42 1.22
0.99 1.11 1.14 1.13
2.54 1.50 0.38 0.73
1.21 1.05 2.19 1.22aselin
N
70.
8.
84.
63.
43.
55.
53.
3.5
0.5
1.0
13.5
56.5
9.7n, 6significant associations, while the ABI was significantly
lity b
r hs-
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risk for more severe PAD. The HR for hs-CRP was no
longer significant (1.12; P  .11).
For CVD mortality at 2 years (Table II), the inverse
association for ABI was the only significant predictor, al-
though dyslipidemia was borderline (HR 2.54; P .055).
At 6.6 years, age, gender, diabetes, ABI, other CVD, hyper-
tension, and dyslipidemia all significantly predicted CVD
mortality. Although theHR for hs-CRPwas greater at 2 years
(1.21) than at 6.6 years (1.05), neither HR was statistically
Fig 1. Total morta
Fig 2. Test characteristics for total mortality fosignificant. For non-CVD mortality, hs-CRP was the onlysignificant predictor at 2 years of follow-up (HR 2.19; P
.001). Only age was a significant predictor at 6.6 years.
Fig 1 shows Kaplan-Meier survival curves for quartiles of
hs-CRP for total mortality. Over the first 2 years, there was a
sharp divergence in risk for higher levels of hs-CRP, followed
by roughly parallel curves for the remainder of follow-up,
visually confirming the greater hazard for hs-CRP over the
first 2 years. Fig 2 shows the test characteristics of the upper
half vs the lower half of hs-CRP values at 1, 2, and average 6.6
years of follow-up. The sensitivity decreases over time, from
y hs-CRP quartile.
CRP above vs at or below the 50th percentile.75% to 60% to 50%, while the specificity remains similar at
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increased, the positive predictive value increased, and the
negative predictive value decreased. These results confirm the
greater early hazard of hs-CRP.
Table III shows standard risk marker and biomarker
contributions to the C statistic and the IDI for total mor-
tality at 2 and 6.6 years. The first two rows are for standard
risk markers alone and hs-CRP alone, followed by standard
risk markers and hs-CRP. The next row is the difference in
the C-statistic with vs without hs-CRP. At 2 years, hs-CRP
was a strong predictor variable, with a C statistic of 0.635,
compared with 0.668 for all the standard risk markers
combined. Addition of hs-CRP to the standard riskmarkers
increased the C-statistic by .019, an increase that was not
significant (P  .11) in part due to the sample size. In
contrast, at full follow-up, the C statistic for hs-CRP was
much smaller (0.545) compared with the standard risk
markers (.654), with only a trivial 0.002 (P  .55) addi-
tional increment for hs-CRP. The IDI for hs-CRP, a mea-
sure of the degree of correct reclassification of fatal and
nonfatal outcomes, was highly significant for hs-CRP at 2
years (P  .023), but not at 6.6 years (P  .307).
DISCUSSION
An important unresolved question is the degree to which
novel biomarkers, and for that matter standard risk factors,
predict whowill or will not have aCVDevent. There is debate
over the use of ROC curves, C-statistics, R-squared, measures
of misclassification, or other methodologies to assess the in-
dependent incremental value of a given risk factor.18,19,21-24
In fact, age and gender are the major drivers of risk equations
in population-based studies,18 and, if extant CVD is present,
that also serves as a major driver.25 Other variables, even
potent risk factors, typically add only small amounts of addi-
tional discrimination.18 These data in PAD patients empha-
size the importance of the follow-up time in this setting.
Mortality rates were high, and at 2 years of follow-up, hs-CRP
contributed in terms of prediction of total mortality. How-
ever, at full follow-up, the standard risk markers dominated
theC-statistic. Thus, the questionof independent incremental
contributors to the risk equation may depend on the baseline
risk composition of the cohort and the length of the risk
Table III. Coxmodel C statistics and IDI P values for all-
cause mortality at 2 years and full follow-up (mean, 6.6 years)
Riskmarkers Year 2 Year 6.6
Standard risk factors .668 .654
hs-CRP alone .635 .545
Standard RFs  hs-CRP .687 .658
Difference in C statistic
adding hs-CRP to
standard RFs .019 (P  .11) .004 (P  .55)
IDI P value adding hs-CRP
to standard risk factors .023 .307
IDI, Integrated discrimination improvement.period in question.Our hypothesis that inflammatory biomarkers, here hs-
CRP, would show a stronger relation to short- vs longer-term
mortality was strongly supported. The hazard ratios at year 2
were attenuated substantially by an average of 6.6 years of
follow-up. None of the other biomarkers significantly pre-
dicted mortality.
In the Cardiovascular Health Study of older participants,
a report employing a prospective nested case-control design
found a stronger association of hs-CRP for earlier CVDevents
than latter, but significant results were limited to women with
subclinical CVD at baseline.6 A recent report from the same
cohort analyzing the entire group confirmed that hs-CRP
predicted early CVD and total death (within 3 years) much
stronger than latter deaths, but the results were stronger in
men.10 In the Quebec Cardiovascular Study (men only),
hs-CRP predicted coronary heart disease events only within 2
years of baseline and only in men 56 years of age.8 In the
Honolulu Heart Program (men only), hs-CRP predicted in-
cident myocardial infarction primarily in participants 56
years of age, but this association lessened with long-term
(15 years) follow-up.9 In a study of PAD patients, SAA,
hs-CRP, and D-dimer all predicted CVD and total mortality
in the first 2 years of follow-up, but only D-dimer showed an
association at 3 years and only for CVDmortality.11 None of
the above studies utilized C statistics or measures of misclas-
sification to quantify the additional discrimination provided
by biomarkers. The Edinburgh Study indicated little addi-
tional contribution of individual biomarkers to ROC curves,
but only presented data for the full follow-up (mean, 17
years).3
A recent study looked at four biomarkers: hs-CRP,
troponin 1, NT-pro-BNP, and cystatin C, in a cohort of
elderly men with a median follow-up of 10 years.5 Each of
these biomarkers independently contributed to CVD
death, and the improvement in the C statistic for these four
biomarkers combined was greater in the whole cohort
(0.102) than in the group free of disease at baseline
(0.059). In contrast to our results and the several other
studies,6,8-11 they apparently did not see a time-dependent
relationship for hs-CRP, although results stratified by fol-
low-up time were not presented.
In patients with PAD, mortality is primarily from CVD
causes.12 The proportion of CVD death in our cohort is
conservative, since we coded only the underlying cause of
death. In fact, many “non-CVD deaths” had CVD causes
listed as contributing, and for at least some other “non-
CVD deaths,” unlisted CVD conditions likely contributed.
Thus, in a PAD cohort, total mortality is the most reliable
outcome measure, and the apparent stronger association of
hs-CRP with (short-term) non-CVD vs CVD mortality
should be interpreted with caution.
Standard CVD risk factors generally showed significant
associations with total andCVDmortality at full follow-up. In
this elderly population with a heavy CVD burden, the vast
majority of ever-smokers were ex-smokers, and this likely
attenuated the results for the pack-years variable. The results
for dyslipidemia were interesting. The strong association for
CVDmortality at 2 and 6.6 years was balanced by a “protec-
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“non-CVD deaths,” resulting in a null association for total
mortality. Since the dyslipidemia variable was primarily high
lipids, with treatment playing a lesser role, these data are
consistent with the expected significant role for dyslipidemia
in CVD mortality and possible reduced lipid values from
chronic illness leading to non-CVD mortality.
Our study has a number of limitations. First, the dis-
tinction between CVD and non-CVD mortality in this
cohort is somewhat problematic. Thus, more confidence
should be placed in the total mortality results, where the
misclassification rate is near zero, than in the cause-specific
results. Second, assessment of standard CVD risk factors is
somewhat problematic, given extensive treatment in this
high-risk cohort. Nonetheless, CVD risk factors predicted
CVD mortality. Third, we had a single baseline assessment
of biomarkers, which may not have reflected earlier or later
measures had they been available. However, such misclas-
sification would have biased results toward the null, sug-
gesting our results are likely conservative.
We conclude that a measure of inflammation, hs-CRP,
was a strong predictor of short-term mortality in a PAD
cohort, but that its predictive value diminished over time.
Recent data suggest that elevations in hs-CRP result from
the atherosclerotic process rather than cause it.26 Either
way, elevated hs-CRP is a strong predictor of short-term
risk and indicates PAD patients who should be receiving
aggressive risk factor modification, including smoking ces-
sation and lipid, hypertension, and antiplatelet therapy.
We thank Nova Rogers for assistance with manuscript
formatting.
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